Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas.

Clinical Hematology International Pub Date : 2022-06-22 eCollection Date: 2022-06-01 DOI:10.1007/s44228-022-00011-9
Ibrahim N Muhsen, Riad El Fakih, Mehdi Hamadani, Hillard M Lazarus, Mohamed A Kharfan-Dabaja, Mahmoud Aljurf
{"title":"Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas.","authors":"Ibrahim N Muhsen,&nbsp;Riad El Fakih,&nbsp;Mehdi Hamadani,&nbsp;Hillard M Lazarus,&nbsp;Mohamed A Kharfan-Dabaja,&nbsp;Mahmoud Aljurf","doi":"10.1007/s44228-022-00011-9","DOIUrl":null,"url":null,"abstract":"<p><p>Primary cutaneous <i>γδ</i> T-cell lymphoma (PCGDTL) is a rare subtype of non-Hodgkin lymphoma (NHL) that arises from T-cells with <i>γδ</i> T-cell receptors. The exact incidence of PCGDTL is unknown, as it is usually lumped with other cutaneous lymphomas, which are also uncommon. It is one of the peripheral T-cell lymphoma (PTCL) subtypes which is known to have a dismal prognosis due to poor response and the paucity of available therapies. Despite the rarity and uncertainties of PCGDTL, a number of studies over the past decade were published about the pathologic, diagnostic, cytogenetic and clinical features of this disease. These diagnostic advances will open the doors to explore new therapeutics for this rare entity, specifically targeted and immune therapies. In this review, we highlight these advances, summarize the contemporary treatment approaches, and shed the light on future potential therapeutic targets.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"4 1-2","pages":"1-10"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358781/pdf/","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Hematology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s44228-022-00011-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Primary cutaneous γδ T-cell lymphoma (PCGDTL) is a rare subtype of non-Hodgkin lymphoma (NHL) that arises from T-cells with γδ T-cell receptors. The exact incidence of PCGDTL is unknown, as it is usually lumped with other cutaneous lymphomas, which are also uncommon. It is one of the peripheral T-cell lymphoma (PTCL) subtypes which is known to have a dismal prognosis due to poor response and the paucity of available therapies. Despite the rarity and uncertainties of PCGDTL, a number of studies over the past decade were published about the pathologic, diagnostic, cytogenetic and clinical features of this disease. These diagnostic advances will open the doors to explore new therapeutics for this rare entity, specifically targeted and immune therapies. In this review, we highlight these advances, summarize the contemporary treatment approaches, and shed the light on future potential therapeutic targets.

Abstract Image

原发性皮肤γ δ t细胞淋巴瘤的临床、诊断和预后特点。
原发性皮肤γδ t细胞淋巴瘤(PCGDTL)是一种罕见的非霍奇金淋巴瘤(NHL)亚型,起源于具有γδ t细胞受体的t细胞。PCGDTL的确切发病率尚不清楚,因为它通常与其他皮肤淋巴瘤合并,这也不常见。它是周围t细胞淋巴瘤(PTCL)亚型之一,由于反应差和缺乏可用的治疗方法,已知预后不佳。尽管PCGDTL的罕见性和不确定性,在过去十年中发表了许多关于该疾病的病理、诊断、细胞遗传学和临床特征的研究。这些诊断的进步将为探索这种罕见的实体的新疗法,特别是靶向和免疫疗法打开大门。在这篇综述中,我们强调了这些进展,总结了当代的治疗方法,并阐明了未来潜在的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信